These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

725 related items for PubMed ID: 23818718

  • 1. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N.
    J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
    [Abstract] [Full Text] [Related]

  • 2. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
    Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL.
    J Rheumatol; 2011 May; 38(5):855-62. PubMed ID: 21285171
    [Abstract] [Full Text] [Related]

  • 3. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A.
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [Abstract] [Full Text] [Related]

  • 4. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [Abstract] [Full Text] [Related]

  • 5. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM, Halland AM, Brzosko M, Burgos-Vargas R, Mela C, Vernon E, Kremer JM.
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [Abstract] [Full Text] [Related]

  • 6. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.
    Landewé R, Østergaard M, Keystone EC, Florentinus S, Liu S, van der Heijde D.
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):180-6. PubMed ID: 25073879
    [Abstract] [Full Text] [Related]

  • 7. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A.
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [Abstract] [Full Text] [Related]

  • 8. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
    van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL.
    J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
    Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.
    Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
    [Abstract] [Full Text] [Related]

  • 10. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [Abstract] [Full Text] [Related]

  • 11. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
    Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.
    Rheumatology (Oxford); 2014 May; 53(5):904-13. PubMed ID: 24441150
    [Abstract] [Full Text] [Related]

  • 12. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT.
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [Abstract] [Full Text] [Related]

  • 13. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
    Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, Flipo RM, Mulleman D, Berenbaum F, Zarnitsky C, Schaeverbeke T, Fardellone P, Dougados M.
    Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
    [Abstract] [Full Text] [Related]

  • 15. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, Landewé R, Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D.
    Arthritis Res Ther; 2015 Sep 10; 17(1):245. PubMed ID: 26353833
    [Abstract] [Full Text] [Related]

  • 16. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr 10; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun 10; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

  • 18. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
    Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH.
    J Rheumatol; 2009 Jul 10; 36(7):1429-41. PubMed ID: 19369462
    [Abstract] [Full Text] [Related]

  • 19. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.
    Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG.
    Ann Rheum Dis; 2006 Jun 10; 65(6):753-9. PubMed ID: 16308341
    [Abstract] [Full Text] [Related]

  • 20. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
    Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R.
    Arthritis Rheum; 2011 Mar 10; 63(3):609-21. PubMed ID: 21360490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.